FDA Disapproves 6,500 Flavored E-cigarettes From Marketing
FDA Disapproves 6,500 Flavored E-cigarettes From Marketing
Introduction
Ten companies that combined produce and market roughly 6,500 flavored e-liquid and e-cigarette products were given marketing denial orders by the U.S. Food and Drug Administration (FDA).
According to the health authority, these businesses cannot promote or distribute the items in the United States, and merchants that do so run the danger of facing FDA enforcement action. FDA must provide a formal marketing order before any firm may legitimately promote a new tobacco product in the United States. However, a marketing denial order is issued if the health regulator decides it is unsafe for the general public's health.
Imperial Vapors LLC, Savage Enterprises, and Big Time Vapes are just a few of the firms the FDA cited as having gotten rejection orders. The FDA stated that it will not reveal the identities of the other two businesses, however, in order to preserve any potentially sensitive commercial information.
According to the FDA, the premarket tobacco product applications (PMTAs) filed for a range of flavor-infused e-cigarette products did not offer enough proof to support the claim that allowing their sale would be in the public's best interest.
The health regulator has prohibited tastes, including citrus, strawberry cheesecake, cool mint, and menthol. Six e-cigarette brands from Altria Group Inc.'s (MO.N) NJOY, on the other hand, have acquired full FDA clearance.
Altria was formerly an investor in Juul, another manufacturer of e-cigarettes, but Juul is still working to have their goods approved. The FDA momentarily prohibited Juul's products last year but later put the decision on hold and agreed to review after the firm filed an appeal.
Latest News
DOJ Opposes JnJ’s Texas Bankruptcy Move in Talc Lawsuit Cases
The U.S. Department of Justice (DOJ) recently opposed Johnson & Johnson’s latest attempt to use bankruptcy to resolve tens of thousands of…
Opioid addiction market to reach $2.4B by 2033
The opioid addiction market across eight major markets (8MM) is projected to grow at a compound annual growth rate (CAGR) of 1.8% from $…